Proton beam therapy for the treatment of uveal melanoma in Scotland

Abstract

PBT is reserved for the treatment of mainly medium-sized and large-sized uveal melanomas in Scotland. The eye retention and disease-specific survival rates confirm its suitability as an eye-preserving primary treatment in these patients. It is evident that PBT is a conservative treatment option for uveal melanoma, including those of larger size.

Robotic radiosurgery for the treatment of medium and large uveal melanoma

“…According to COMS, the predicted 5-year disease-specific mortality rate was 31-35% for large tumors, 10% for medium tumors, and 1% for small tumors [12,15]. Our 5-year disease-specific mortality was comparable to other studies [8,20,22]. Local effective therapy seems important as delay or refusal of treatment is associated with an increased incidence of metastatic disease and/or death compared with mortality rates of patients who received prompt treatment [30,31].…”

“…Treatment complications included radiation retinopathy in 66% of patients, radiation optic neuropathy in 51%, secondary cataract in 36%, and secondary glaucoma in 17%. Macdonald et al [8] have reported on 147 patients treated between 1993 and 2008 with proton beam radiotherapy for ciliary body and uveal melanoma not eligible for brachytherapy due to tumor size, location, or shape. In their report, they found an enucleation rate of 22.4% at a mean time of 23.8 months.…”

Robotic radiosurgery for the treatment of medium and large uveal melanoma

“…According to COMS, the predicted 5-year disease-specific mortality rate was 31-35% for large tumors, 10% for medium tumors, and 1% for small tumors [12,15]. Our 5-year disease-specific mortality was comparable to other studies [8,20,22]. Local effective therapy seems important as delay or refusal of treatment is associated with an increased incidence of metastatic disease and/or death compared with mortality rates of patients who received prompt treatment [30,31].…”

“…Treatment complications included radiation retinopathy in 66% of patients, radiation optic neuropathy in 51%, secondary cataract in 36%, and secondary glaucoma in 17%. Macdonald et al [8] have reported on 147 patients treated between 1993 and 2008 with proton beam radiotherapy for ciliary body and uveal melanoma not eligible for brachytherapy due to tumor size, location, or shape. In their report, they found an enucleation rate of 22.4% at a mean time of 23.8 months.…”

Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas

“…In a review of all globeconserving treatments for choroidal melanomas, the local failure rate of PBT was 4.2% as opposed to 9.6% average for brachytherapy from all radioisotopes [23]. In our previously published series on PBT for choroidal and ciliary body melanomas, patients achieved a 5-year disease-specific survival rate of 87.7% and an actuarial 5-year eye retention rate of 71.3% [24]. In a study comparing stereotactic radiosurgery and PBT for choroidal melanoma over a 10-year period, both modalities had comparable tumour control and eye retention.…”

Risk factors associated with secondary enucleation after fractionated stereotactic radiotherapy in uveal melanoma

“…() and Macdonald et al. () report 11–24% following proton beam radiotherapy, Furdova et al. () report 12% after one step LINAC‐based stereotactic radiosurgery and around 11% for conservative therapies combined (Damato & Lecuona ) all with a 5–15 years follow‐up.…”

Robotic radiosurgery for the treatment of medium and large uveal melanoma

“…According to COMS, the predicted 5-year disease-specific mortality rate was 31-35% for large tumors, 10% for medium tumors, and 1% for small tumors [12,15]. Our 5-year disease-specific mortality was comparable to other studies [8,20,22]. Local effective therapy seems important as delay or refusal of treatment is associated with an increased incidence of metastatic disease and/or death compared with mortality rates of patients who received prompt treatment [30,31].…”

“…Treatment complications included radiation retinopathy in 66% of patients, radiation optic neuropathy in 51%, secondary cataract in 36%, and secondary glaucoma in 17%. Macdonald et al [8] have reported on 147 patients treated between 1993 and 2008 with proton beam radiotherapy for ciliary body and uveal melanoma not eligible for brachytherapy due to tumor size, location, or shape. In their report, they found an enucleation rate of 22.4% at a mean time of 23.8 months.…”

Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas

“…In a review of all globeconserving treatments for choroidal melanomas, the local failure rate of PBT was 4.2% as opposed to 9.6% average for brachytherapy from all radioisotopes [23]. In our previously published series on PBT for choroidal and ciliary body melanomas, patients achieved a 5-year disease-specific survival rate of 87.7% and an actuarial 5-year eye retention rate of 71.3% [24]. In a study comparing stereotactic radiosurgery and PBT for choroidal melanoma over a 10-year period, both modalities had comparable tumour control and eye retention.…”

Risk factors associated with secondary enucleation after fractionated stereotactic radiotherapy in uveal melanoma

“…() and Macdonald et al. () report 11–24% following proton beam radiotherapy, Furdova et al. () report 12% after one step LINAC‐based stereotactic radiosurgery and around 11% for conservative therapies combined (Damato & Lecuona ) all with a 5–15 years follow‐up.…”

Robotic radiosurgery for the treatment of medium and large uveal melanoma

“…According to COMS, the predicted 5-year disease-specific mortality rate was 31-35% for large tumors, 10% for medium tumors, and 1% for small tumors [12,15]. Our 5-year disease-specific mortality was comparable to other studies [8,20,22]. Local effective therapy seems important as delay or refusal of treatment is associated with an increased incidence of metastatic disease and/or death compared with mortality rates of patients who received prompt treatment [30,31].…”

“…Treatment complications included radiation retinopathy in 66% of patients, radiation optic neuropathy in 51%, secondary cataract in 36%, and secondary glaucoma in 17%. Macdonald et al [8] have reported on 147 patients treated between 1993 and 2008 with proton beam radiotherapy for ciliary body and uveal melanoma not eligible for brachytherapy due to tumor size, location, or shape. In their report, they found an enucleation rate of 22.4% at a mean time of 23.8 months.…”

Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas

“…In a review of all globeconserving treatments for choroidal melanomas, the local failure rate of PBT was 4.2% as opposed to 9.6% average for brachytherapy from all radioisotopes [23]. In our previously published series on PBT for choroidal and ciliary body melanomas, patients achieved a 5-year disease-specific survival rate of 87.7% and an actuarial 5-year eye retention rate of 71.3% [24]. In a study comparing stereotactic radiosurgery and PBT for choroidal melanoma over a 10-year period, both modalities had comparable tumour control and eye retention.…”

Risk factors associated with secondary enucleation after fractionated stereotactic radiotherapy in uveal melanoma

“…() and Macdonald et al. () report 11–24% following proton beam radiotherapy, Furdova et al. () report 12% after one step LINAC‐based stereotactic radiosurgery and around 11% for conservative therapies combined (Damato & Lecuona ) all with a 5–15 years follow‐up.…”